GI Cancer Experts on Notable Updates Shared During the 2025 ASCO Annual Meeting
Hematologists Highlight Notable Insights From the 2025 EHA Congress
Post Hoc Analysis Shows Imetelstat Drives Benefit in RS-Negative, Lower-Risk MDS
Bexobrutideg Is Tolerable and Yields High Response Rates in Relapsed/Refractory Waldenström Macroglobulinemia
